Showing results (291-300 of 308) with videos related to
Sort By:
Pageof 31
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist TherapyEvan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.Journal of Hepatology|September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J Dore, Brian Conway, Yan Luo, et al.BMC Medicine|January 14, 2022
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infectionFeargal J Ryan, Christopher M Hope, Makutiro G Masavuli, et al.Annals of the Rheumatic Diseases|October 13, 2017
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiativeJasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, et al.The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.PDA Journal of Pharmaceutical Science and Technology|April 20, 2018
Implementation of Plate Imaging for Demonstration of Monoclonality in Biologics Manufacturing DevelopmentKyle Zingaro, David Shaw, Jerry Carson, et al.Pageof 31